Autonomix Medical Inc.
AMIX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AMIX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AMIX
Autonomix Medical Inc. is a development-stage medical device company focused on treating pain associated with pancreatic cancer, with no approved products or revenue, and cash resources projected to fund operations only into early 2027.
Key risk: Cash runway limited
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Autonomix Medical Inc. is a development-stage medical device company focused on treating pain associated with pancreatic cancer, with no approved products or revenue, and cash resources projected to fund operations only into early 2027.
- Autonomix Medical is initially focusing on the treatment of pain associated with pancreatic cancer as its first proposed indication for use [sec_mda · as of 2024-08-13].
- As of June 30, 2026, the company had cash of $3.5 million and working capital of $3.1 million [sec_mda · as of 2026-08-13].
- The company estimates its current cash resources are sufficient to fund operations into but not beyond the first calendar quarter of 2027 [sec_mda · as of 2026-08-13].
- Autonomix has incurred significant losses since inception and expects to continue experiencing operating losses and negative cash flow for the foreseeable future [sec_mda · as of 2026-05-27].
- The company will need to raise additional capital to meet its obligations and execute its business plan, with prior estimates of needing $30 to $36 million to reach commercialization of its first indication [sec_mda · as of 2026-02-11].
What works
- The company has a clear initial focus on a high-need indication—pain associated with pancreatic cancer—which could address a significant unmet medical need [sec_mda · as of 2024-08-13].
- Autonomix has historically funded operations through debt and equity sales, demonstrating some ability to access capital markets [sec_mda · as of 2026-08-13].
What to weigh
- The company has no FDA-cleared or commercially viable products and may never achieve regulatory clearance or market acceptance [sec_mda · as of 2026-05-27].
- Cash runway is limited to early 2027, and the company will require substantial additional financing to continue operations and complete clinical trials [sec_mda · as of 2026-08-13].
- Autonomix operates in a very competitive and rapidly changing environment, with numerous risks that could adversely impact its business [sec_mda · as of 2026-05-27].
From the filings
Quoted directly from source documents.
Initial focus on pancreatic cancer pain
“We are initially focusing on the treatment of pain associated with pancreatic cancer and we have designed our commercialization efforts around this as our first proposed indication for use.”
SEC MD&A · August 13, 2024
History of losses and expectation of continued losses
“We have incurred significant losses since our inception and expect to continue to experience operating losses and negative cash flow for the foreseeable future.”
SEC MD&A · May 27, 2026
Need for additional capital to commercialize
“We estimate that we will require additional financing of approximately $30 to $35 million to fund our operations to commercialization of our first indication.”
SEC MD&A · February 13, 2025
Risks & what to watch (4)›
Key risks
- Cash runway limited — Cash of $3.5M as of June 30, 2026 is expected to fund operations only into early 2027 [sec_mda · as of 2026-08-13].
- No approved products — Products may never be cleared by the FDA or become commercially viable [sec_mda · as of 2026-05-27].
- Need for substantial capital — Company estimates needing $30-$36M to reach commercialization; no assurance of funding [sec_mda · as of 2026-02-11].
- Competitive and changing market — Operates in a very competitive and rapidly changing environment with unquantifiable risks [sec_mda · as of 2026-05-27].
What to watch
- Ability to raise additional capital before cash runway ends in early 2027 [sec_mda · as of 2026-08-13].
- Progress of clinical trials for pain associated with pancreatic cancer [sec_mda · as of 2024-08-13].
- Any FDA regulatory submissions or clearances for the company's products [sec_mda · as of 2026-05-27].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Autonomix Medical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Autonomix Medical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
3.1 months
D/E 0.26
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$79K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 175,621 | $69K |
| bank of montreal /can/ | 25,000 | $10K |
| pnc financial services group, inc. | 1,588 | $619 |
| harbour investments, inc. | 10 | $4 |
| swan capital llc | 10 | $4 |
| key capital management, inc | 10 | $4 |
| farther finance advisors, llc | 10 | $4 |
| national bank of canada /fi/ | 7 | $3 |
Short Interest
as of May 12, 2026- % of float
- 2.0%
- Days to cover
- 1.8
- Shares short
- 230,946
- Daily short volume (May 7, 2026)
- 72.5%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AMIX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Autonomix Medical Inc.?
Autonomix Medical Inc. is a development-stage medical device company focused on treating pain associated with pancreatic cancer, with no approved products or revenue, and cash resources projected to fund operations only into early 2027.
Who is the CEO of Autonomix Medical Inc.?
Mr. Bradley Hauser is the chief executive officer of Autonomix Medical Inc. (AMIX).
Where is Autonomix Medical Inc. headquartered?
Autonomix Medical Inc. (AMIX) is headquartered in The Woodlands, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.